Sysmex (OTCMKTS:SSMXY) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Sysmex (OTCMKTS:SSMXY) from a strong sell rating to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

Sysmex Price Performance

OTCMKTS SSMXY opened at $12.12 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. The business’s fifty day moving average is $9.85 and its 200 day moving average is $9.20. The company has a market capitalization of $7.63 billion, a PE ratio of 28.86 and a beta of 1.05. Sysmex has a fifty-two week low of $8.01 and a fifty-two week high of $13.49.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.07 by $0.02. The firm had revenue of $825.85 million for the quarter, compared to the consensus estimate of $741.67 million. Sysmex had a return on equity of 7.87% and a net margin of 7.62%.Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Sell-side analysts predict that Sysmex will post 0.38 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.